Navigation Links
Biotech Drops Amid Tough Markets in February
Date:3/3/2008

SAN FRANCISCO, March 3 /PRNewswire/ -- For the second month in a row the capital markets succumbed to fears of inflation and a weakening economy. On the last day of the month the Dow dropped over 300 points after oil prices pushed past $103 per barrel for the first time. Amid these fears, biotech was dragged down with the Burrill Biotech Select Index dropping 4% along with the NASDAQ, down 5% and the Dow, which closed down 3%.

"The biotech sector started 2008 on a positive note, outperforming the major indices in January," said G. Steven Burrill, CEO of Burrill & Company, a San Francisco based global leader in life sciences whose principal activities are in Private Equity, Venture Capital, Merchant Banking and Media. "However, in the wake of negative news from biotech's top performer Onyx Pharmaceuticals, the industry took a hit."

Onyx was the best-performing biotech stock of 2007, notching a one-year return of 440% ... but the company dropped 42.5% in February after reporting its cancer drug Nexavar failed a Phase III study in lung cancer patients. The study was testing the combination of Nexavar and the chemotherapy drugs carboplatin and paclitaxel in patients with non-small-cell lung cancer.

One of the few companies in the Index group to post a gain in February was Genentech (up 8%) on the strength that Avado, a Phase III study evaluating its cancer drug Avastin in combination with docetaxel chemotherapy, met its primary endpoint of prolonging progression-free survival in patients with advanced breast cancer. The Roche-sponsored Avado study investigated the addition of Avastin administered in two different dosages in combination with chemotherapy. Both doses of Avastin in combination with chemotherapy showed "statistically significant improvement" in the time patients lived without their disease advancing compared with chemotherapy and placebo.

The other was Illumina (up 13%). Its fourth-quarter revenue was up an impressive 86%. On the other side of the coin, shares of Vertex Pharmaceuticals were down 14% after reporting that a wider fourth-quarter loss will retard its 2008 outlook, which was below Wall Street expectations.

The Burrill Biotech Mid-Cap Index dropped 9% as investors migrated away from these companies. "Even though the pharmaceutical and biotech sectors are among the best for investors to be in during a recession, it is the blue-chip companies that they seek out. In difficult market conditions emerging biotech companies are viewed as more risky investments which is why most companies in the group lost value," noted Burrill.

Biotech IPOs remain on hold

The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and Archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage. It priced its 1.1 million shares offering at $5.25 the midpoint of a revised range. The company had originally filed for an offering of 3.6 million shares at a range of $14-$16.

Market cap

The industry's market cap closed at $440 billion, unchanged for February. Genentech's market cap closed the month at $79B and second placed Amgen slipped 2% to $49B. Close on Amgen's heels is Gilead Sciences, which closed February at $44B.

Biotech Indices

Index 12/29/06 12/31/07 1/31/08 2/29/08 % %

change change

Month Year

Burrill Biotech

Select 303.96 331.52 331.31 318.05 -4.00% -4.06%

Burrill Large

Cap Biotech 424.56 437.71 438.87 434.25 -1.05% -0.79%

Burrill Mid-Cap

Biotech 171.55 201.89 179.33 161.7 -9.83% -19.91%

Burrill Small

Cap Biotech 143.6 137.6 148.3 150.15 1.25% 9.12%

Burrill Genomics 101.69 104.29 93.64 86.83 -7.27% -16.74%

Burrill AgBio 124.52 198.83 193.82 197.08 1.68% -0.88%

Burrill

Industrial 150.85 158.66 146.41 160.09 9.34% 0.90%

Burrill

Diagnostic 122.79 159.43 151.53 152.72 0.79% -4.21%

Burrill

Nutraceutical 629.56 593.04 556.24 546.94 -1.67% -7.77%

NASDAQ 2415.29 2652.28 2389.86 2271.48 -4.95% -14.36%

DJIA 12463.15 13264.82 12650.36 12266.39 -3.04% -7.53%

Russell 2000 787.66 766.03 713.3 686.18 -3.80% -10.42%

Amex Biotech 754.25 786.5 749.38 721.95 -3.66% -8.21%

Amex Pharma 345.06 338.52 316.45 305.15 -3.57% -9.86%


'/>"/>
SOURCE Burrill & Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic Engineering & Biotechnology News reports on advances in miRNA
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
4. Sigma-Aldrich Names Helge Bastian New VP of Global Marketing for Research Biotech
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
7. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
8. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
9. Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
10. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
11. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):